FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2326-2333 December 11, 2003 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Colvin, R. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background With improved immunosuppression and early allograft survival, chronic allograft nephropathy has become the dominant cause of kidney-transplant failure.

Methods We evaluated the natural history of chronic allograft nephropathy in a prospective study of 120 recipients with type 1 diabetes, all but 1 of whom had received kidney–pancreas transplants. We obtained 961 kidney-transplant–biopsy specimens taken regularly from the time of transplantation to 10 years thereafter.

Results Two distinctive phases of injury were evident as chronic allograft nephropathy evolved. An initial phase of early tubulointerstitial damage from ischemic injury (P<0.05), prior severe rejection (P<0.01), and subclinical rejection (P<0.01) predicted mild disease by one year, which was present in 94.2 percent of patients. Early subclinical rejection was common (affecting 45.7 percent of biopsy specimens at three months), and the risk was increased by the occurrence of a prior episode of severe rejection and reduced by tacrolimus and mycophenolate therapy (both P<0.05) and gradually abated after one year. Both subclinical rejection and chronic rejection were associated with increased tubulointerstitial damage (P<0.01). Beyond one year, a later phase of chronic allograft nephropathy was characterized by microvascular and glomerular injury. Chronic rejection (defined as persistent subclinical rejection for two years or longer) was uncommon (5.8 percent). Progressive high-grade arteriolar hyalinosis with luminal narrowing, increasing glomerulosclerosis, and additional tubulointerstitial damage was accompanied by the use of calcineurin inhibitors. Nephrotoxicity, implicated in late ongoing injury, was almost universal at 10 years, even in grafts with excellent early histologic findings. By 10 years, severe chronic allograft nephropathy was present in 58.4 percent of patients, with sclerosis in 37.3 percent of glomeruli. Tubulointerstitial and glomerular damage, once established, was irreversible, resulting in declining renal function and graft failure.

Conclusions Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes.

Source Information

From the Departments of Renal Medicine (B.J.N., R.J.B., P.J.O., J.R.C.), Tissue Pathology (C.L.-S.F.), and Transplantation Surgery (R.D.M.A.), University of Sydney, Westmead Hospital, Sydney, Australia.

Address reprint requests to Dr. Nankivell at the Department of Renal Medicine, Westmead Hospital, Westmead, 2145 NSW, Australia, or at brian_nankivell{at}wsahs.nsw.gov.au.

Full Text of this Article

Related Letters:

Chronic Allograft Nephropathy
Ponticelli C., Torras J., Herrero-Fresneda I., Grinyo J. M., Pietrzyk M., Hoffmann U., Krämer B. K., Nankivell B. J., Chapman J. R.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:1254-1256, Mar 18, 2004. Correspondence

This article has been cited by other articles:

• Lloberas, N., Torras, J., Alperovich, G., Cruzado, J. M., Gimenez-Bonafe, P., Herrero-Fresneda, I., Franquesa, M.{m. d.}l., Rama, I., Grinyo, J. M. (2008). Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 0: gfn223v1-gfn223 [Abstract] [Full Text]  
• Seron, D., Arns, W., Chapman, J. R. (2008). Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies. Nephrol Dial Transplant 0: gfn130v1-gfn130 [Full Text]  
• Pozdzik, A. A., Salmon, I. J., Husson, C. P., Decaestecker, C., Rogier, E., Bourgeade, M.-F., Deschodt-Lanckman, M. M., Vanherweghem, J.-L., Nortier, J. L. (2008). Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. Nephrol Dial Transplant 0: gfn140v1-gfn140 [Abstract] [Full Text]  
• Capasso, G., Di Gennaro, C. I., Ragione, F. D., Manna, C., Ciarcia, R., Florio, S., Perna, A., Pollastro, R. M., Damiano, S., Mazzoni, O., Galletti, P., Zappia, V. (2008). In vivo effect of the natural antioxidant hydroxytyrosol on cyclosporine nephrotoxicity in rats. Nephrol Dial Transplant 23: 1186-1195 [Abstract] [Full Text]  
• De Antonio, S. R., Saber, L. T. S., Chriguer, R. S., de Castro, M. (2008). Glucocorticoid resistance in dialysis patients may impair the kidney allograft outcome. Nephrol Dial Transplant 23: 1422-1428 [Abstract] [Full Text]  
• Blasco, V., Leone, M., Antonini, F., Geissler, A., Albanese, J., Martin, C. (2008). Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 100: 504-508 [Abstract] [Full Text]  
• Jevnikar, A. M., Mannon, R. B. (2008). Late Kidney Allograft Loss: What We Know about It, and What We Can Do about It. CJASN 3: S56-S67 [Abstract] [Full Text]  
• Srinivas, T. R., Meier-Kriesche, H.-U. (2008). Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects: Objectives and Interim Result. CJASN 3: S101-S116 [Abstract] [Full Text]  
• Kukla, A., Adulla, M., Pascual, J., Samaniego, M., Nanovic, L., Becker, B. N., Djamali, A. (2008). CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant 23: 693-700 [Abstract] [Full Text]  
• Matas, A. J., Pavlakis, M. (2007). Resolved: In Minimizing Kidney Transplant Immunosuppression, Steroids Should Go before Calcineurin Inhibitors: Pro. J. Am. Soc. Nephrol. 18: 3026-3030 [Abstract] [Full Text]  
• Zitt, N., Kollerits, B., Neyer, U., Mark, W., Heininger, D., Mayer, G., Kronenberg, F., Lhotta, K. (2007). Cigarette smoking and chronic allograft nephropathy. Nephrol Dial Transplant 22: 3034-3039 [Abstract] [Full Text]  
• Brouard, S., Mansfield, E., Braud, C., Li, L., Giral, M., Hsieh, S.-c., Baeten, D., Zhang, M., Ashton-Chess, J., Braudeau, C., Hsieh, F., Dupont, A., Pallier, A., Moreau, A., Louis, S., Ruiz, C., Salvatierra, O., Soulillou, J.-P., Sarwal, M. (2007). Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl. Acad. Sci. USA 104: 15448-15453 [Abstract] [Full Text]  
• Moore, J., Tan, K., Cockwell, P., Krishnan, H., McPake, D., Ready, A., Mellor, S., Hamsho, A., Ball, S., Lipkin, G., Borrows, R. (2007). Predicting early renal allograft function using clinical variables. Nephrol Dial Transplant 22: 2669-2677 [Abstract] [Full Text]  
• Elimelakh, M., Dayton, V., Park, K. S., Gruessner, A. C., Sutherland, D., Howe, R. B., Reding, M. T., Eastlund, T., van Burik, J.-A., Singleton, T. P., Gruessner, R. W., Key, N. S. (2007). Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. haematol 92: 1029-1036 [Abstract] [Full Text]  
• Djamali, A. (2007). Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am. J. Physiol. Renal Physiol. 293: F445-F455 [Abstract] [Full Text]  
• Joy, M. S., Hogan, S. L., Thompson, B. D., Finn, W. F., Nickeleit, V. (2007). Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 22: 1963-1968 [Abstract] [Full Text]  
• Bobadilla, N. A., Gamba, G. (2007). New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am. J. Physiol. Renal Physiol. 293: F2-F9 [Abstract] [Full Text]  
• Goes, N. B., Colvin, R. B. (2007). Case 12-2007 -- A 56-Year-Old Woman with Renal Failure after Heart-Lung Transplantation. NEJM 356: 1657-1665 [Full Text]  
• Fiorina, P., Perseghin, G., De Cobelli, F., Gremizzi, C., Petrelli, A., Monti, L., Maffi, P., Luzi, L., Secchi, A., Del Maschio, A. (2007). Altered Kidney Graft High-Energy Phosphate Metabolism in Kidney-Transplanted End-Stage Renal Disease Type 1 Diabetic Patients: A cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care 30: 597-603 [Abstract] [Full Text]  
• Djamali, A., Sadowski, E. A., Muehrer, R. J., Reese, S., Smavatkul, C., Vidyasagar, A., Fain, S. B., Lipscomb, R. C., Hullett, D. H., Samaniego-Picota, M., Grist, T. M., Becker, B. N. (2007). BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. Am. J. Physiol. Renal Physiol. 292: F513-F522 [Abstract] [Full Text]  
• Tse, K C, Lam, M F, Tang, S C., Tang, C S., Chan, T M (2007). A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16: 46-51 [Abstract]  
• Heine, G. H., Reichart, B., Ulrich, C., Kohler, H., Girndt, M. (2007). Do ultrasound renal resistance indices reflect systemic rather than renal vascular damage in chronic kidney disease?. Nephrol Dial Transplant 22: 163-170 [Abstract] [Full Text]  
• Zeyda, M., Geyeregger, R., Poglitsch, M., Weichhart, T., Zlabinger, G. J., Koyasu, S., Horl, W. H., Stulnig, T. M., Watschinger, B., Saemann, M. D. (2007). Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-{kappa}B in immunological synapse formation. J. Leukoc. Biol. 81: 319-327 [Abstract] [Full Text]  
• Kambham, N., Nagarajan, S., Shah, S., Li, L., Salvatierra, O., Sarwal, M. M. (2007). A Novel, Semiquantitative, Clinically Correlated Calcineurin Inhibitor Toxicity Score for Renal Allograft Biopsies. CJASN 2: 135-142 [Abstract] [Full Text]  
• Perez-Rojas, J., Blanco, J. A., Cruz, C., Trujillo, J., Vaidya, V. S., Uribe, N., Bonventre, J. V., Gamba, G., Bobadilla, N. A. (2007). Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am. J. Physiol. Renal Physiol. 292: F131-F139 [Abstract] [Full Text]  
• Tang, S. C.-W., Chan, K. W., Tang, C. S.-O., Lam, M. F., Leung, C. Y., Tse, K. C., Li, C. S., Ho, Y. W., Tong, M. K.-L., Lai, K. N., Chan, T. M., for the Hong Kong Nephrology Study Group, (2006). Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant 21: 3243-3251 [Abstract] [Full Text]  
• Ruiz, J. C., Campistol, J. M., Sanchez-Fructuoso, A., Rivera, C., Oliver, J., Ramos, D., Campos, B., Arias, M., Diekmann, F. (2006). Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 21: 3252-3257 [Abstract] [Full Text]  
• Najafian, N., Albin, M. J., Newell, K. A. (2006). How Can We Measure Immunologic Tolerance in Humans?. J. Am. Soc. Nephrol. 17: 2652-2663 [Abstract] [Full Text]  
• Beckmann, N., Cannet, C., Zurbruegg, S., Haberthur, R., Li, J., Pally, C., Bruns, C. (2006). Macrophage Infiltration Detected at MR Imaging in Rat Kidney Allografts: Early Marker of Chronic Rejection?. Radiology 240: 717-724 [Abstract] [Full Text]  
• Chapman, J. R., Nankivell, B. J. (2006). Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?. Nephrol Dial Transplant 21: 2060-2063 [Full Text]  
• Djamali, A., Samaniego, M., Muth, B., Muehrer, R., Hofmann, R. M., Pirsch, J., Howard, A., Mourad, G., Becker, B. N. (2006). Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. CJASN 1: 623-640 [Abstract] [Full Text]  
• Harmon, W., Meyers, K., Ingelfinger, J., McDonald, R., McIntosh, M., Ho, M., Spaneas, L., Palmer, J. A., Hawk, M., Geehan, C., Tinckam, K., Hancock, W. W., Sayegh, M. H. (2006). Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation. J. Am. Soc. Nephrol. 17: 1735-1745 [Abstract] [Full Text]  
• Verkoelen, C. F. (2006). Crystal Retention in Renal Stone Disease: A Crucial Role for the Glycosaminoglycan Hyaluronan?. J. Am. Soc. Nephrol. 17: 1673-1687 [Abstract] [Full Text]  
• Soulillou, J.-P., Giral, M. (2006). Influence of graft characteristics on the outcome of kidney transplantation.. NEJM 354: 2060-2062 [Full Text]  
• Mannon, R. B., Kirk, A. D. (2006). Beyond Histology: Novel Tools to Diagnose Allograft Dysfunction. CJASN 1: 358-366 [Abstract] [Full Text]  
• Diekmann, F., Campistol, J. M. (2006). Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21: 562-568 [Full Text]  
• Roos-van Groningen, M. C., Scholten, E. M., Lelieveld, P. M., Rowshani, A. T., Baelde, H. J., Bajema, I. M., Florquin, S., Bemelman, F. J., de Heer, E., de Fijter, J. W., Bruijn, J. A., Eikmans, M. (2006). Molecular Comparison of Calcineurin Inhibitor-Induced Fibrogenic Responses in Protocol Renal Transplant Biopsies. J. Am. Soc. Nephrol. 17: 881-888 [Abstract] [Full Text]  
• Saurina, A., Campistol, J. M., Piera, C., Diekmann, F., Campos, B., Campos, N., de las Cuevas, X., Oppenheimer, F. (2006). Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21: 488-493 [Abstract] [Full Text]  
• Rush, D. (2006). Protocol Transplant Biopsies: An Underutilized Tool in Kidney Transplantation. CJASN 1: 138-143 [Full Text]  
• Rowshani, A. T., Scholten, E. M., Bemelman, F., Eikmans, M., Idu, M., van Groningen, M. C.R., Surachno, J. S., Mallat, M. J.K., Paul, L. C., de Fijter, J. W., Bajema, I. M., ten Berge, I., Florquin, S. (2006). No Difference in Degree of Interstitial Sirius Red-Stained Area in Serial Biopsies from Area under Concentration-over-Time Curves-Guided Cyclosporine versus Tacrolimus-Treated Renal Transplant Recipients at One Year. J. Am. Soc. Nephrol. 17: 305-312 [Abstract] [Full Text]  
• Revelo, M. P., Federspiel, C., Helderman, H., Fogo, A. B. (2005). Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-{gamma}. Nephrol Dial Transplant 20: 2812-2819 [Abstract] [Full Text]  
• Stallone, G., Infante, B., Schena, A., Battaglia, M., Ditonno, P., Loverre, A., Gesualdo, L., Schena, F. P., Grandaliano, G. (2005). Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant Patients. J. Am. Soc. Nephrol. 16: 3755-3762 [Abstract] [Full Text]  
• Bumbea, V., Kamar, N., Ribes, D., Esposito, L., Modesto, A., Guitard, J., Nasou, G., Durand, D., Rostaing, L. (2005). Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20: 2517-2523 [Abstract] [Full Text]  
• Vallejos, A., Alperovich, G., Moreso, F., Canas, C., de Lama, M. E., Goma, M., Fulladosa, X., Carrera, M., Hueso, M., Grinyo, J. M., Seron, D. (2005). Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. Nephrol Dial Transplant 20: 2511-2516 [Abstract] [Full Text]  
• Perez-Rojas, J. M., Derive, S., Blanco, J. A., Cruz, C., de la Maza, L. M., Gamba, G., Bobadilla, N. A. (2005). Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am. J. Physiol. Renal Physiol. 289: F1020-F1030 [Abstract] [Full Text]  
• Webster, A. C, Woodroffe, R. C, Taylor, R. S, Chapman, J. R, Craig, J. C (2005). Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331: 810- [Abstract] [Full Text]  
• Chapman, J. R., O'Connell, P. J., Nankivell, B. J. (2005). Chronic Renal Allograft Dysfunction. J. Am. Soc. Nephrol. 16: 3015-3026 [Abstract] [Full Text]  
• Yuan, R., El-Asady, R., Liu, K., Wang, D., Drachenberg, C. B., Hadley, G. A. (2005). Critical Role for CD103+CD8+ Effectors in Promoting Tubular Injury following Allogeneic Renal Transplantation. J. Immunol. 175: 2868-2879 [Abstract] [Full Text]  
• Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., Charpentier, B., the Belatacept Study Group, (2005). Costimulation Blockade with Belatacept in Renal Transplantation. NEJM 353: 770-781 [Abstract] [Full Text]  
• Holzmacher, R., Kendziorski, C., Michael Hofman, R., Jaffery, J., Becker, B., Djamali, A. (2005). Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 20: 1456-1462 [Abstract] [Full Text]  
• Avihingsanon, Y., Ma, N., Pavlakis, M., Chon, W. J., Uknis, M. E., Monaco, A. P., Ferran, C., Stillman, I., Schachter, A. D., Mottley, C., Zheng, X. X., Strom, T. B. (2005). On the Intraoperative Molecular Status of Renal Allografts after Vascular Reperfusion and Clinical Outcomes. J. Am. Soc. Nephrol. 16: 1542-1548 [Abstract] [Full Text]  
• Hauser, I. A., Schaeffeler, E., Gauer, S., Scheuermann, E. H., Wegner, B., Gossmann, J., Ackermann, H., Seidl, C., Hocher, B., Zanger, U. M., Geiger, H., Eichelbaum, M., Schwab, M. (2005). ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation. J. Am. Soc. Nephrol. 16: 1501-1511 [Abstract] [Full Text]  
• Keith, D. S., deMattos, A., Golconda, M., Prather, J., Cantarovich, M., Paraskevas, S., Tchervenkov, J., Norman, D. J. (2005). Factors Associated with Improvement in Deceased Donor Renal Allograft Function in the 1990s. J. Am. Soc. Nephrol. 16: 1512-1521 [Abstract] [Full Text]  
• Ortiz, F., Paavonen, T., Tornroth, T., Koskinen, P., Finne, P., Salmela, K., Kyllonen, L., Gronhagen-Riska, C., Honkanen, E. (2005). Predictors of Renal Allograft Histologic Damage Progression. J. Am. Soc. Nephrol. 16: 817-824 [Abstract] [Full Text]  
• Rao, P. S., Schaubel, D. E., Saran, R. (2005). Impact of graft failure on patient survival on dialysis: a comparison of transplant-naive and post-graft failure mortality rates. Nephrol Dial Transplant 20: 387-391 [Abstract] [Full Text]  
• Winkelmayer, W. C., Kramar, R., Curhan, G. C., Chandraker, A., Endler, G., Fodinger, M., Horl, W. H., Sunder-Plassmann, G. (2005). Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study. J. Am. Soc. Nephrol. 16: 255-260 [Abstract] [Full Text]  
• Sayegh, M. H., Carpenter, C. B. (2004). Transplantation 50 Years Later -- Progress, Challenges, and Promises. NEJM 351: 2761-2766 [Full Text]  
• Hueso, M., Alia, P., Moreso, F., Beltran-Sastre, V., Riera, L., Gonzalez, C., Angel Navarro, M., Grinyo, J. M., Navarro, E., Seron, D. (2004). Angiotensin Converting Enzyme Genotype and Chronic Allograft Nephropathy in Protocol Biopsies. J. Am. Soc. Nephrol. 15: 2229-2236 [Abstract] [Full Text]  
• Kunzendorf, U., Ziegler, E., Kabelitz, D. (2004). FTY720--the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 19: 1677-1681 [Full Text]  
• Poggio, E. D., Clemente, M., Riley, J., Roddy, M., Greenspan, N. S., Dejelo, C., Najafian, N., Sayegh, M. H., Hricik, D. E., Heeger, P. S. (2004). Alloreactivity in Renal Transplant Recipients with and without Chronic Allograft Nephropathy. J. Am. Soc. Nephrol. 15: 1952-1960 [Abstract] [Full Text]  
• Ponticelli, C., Torras, J., Herrero-Fresneda, I., Grinyo, J. M., Pietrzyk, M., Hoffmann, U., Kramer, B. K., Nankivell, B. J., Chapman, J. R. (2004). Chronic Allograft Nephropathy. NEJM 350: 1254-1256 [Full Text]